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__________________________________________ 
 
“Age wave,” “age explosion,” “the aging boomers,” “the graying of America.”  You’ve 
probably been hearing these terms at conferences and cocktail parties alike.  
America has included into its lexicon a host of new terms to describe this unique 
period in history, a period in which our senior citizen population is growing as never 
before.  A demographic shift as profound as this carries with it the potential to 
redefine the foundations of our nation:  our economy, our politics, our home lives 
and, of course, our healthcare. 
 
Caring for a growing elderly population presents many challenges, not the least of 
which is providing appropriate pharmaceutical care.  However, several confounding 
factors contribute to the challenge of providing pharmaceutical care to the elderly.  
First, most older patients have at least two or more chronic diseases for which they 
may be receiving as many as nine or more medications1,2,3. Comorbidity and the 
corresponding need for multi-drug therapy increases the importance of appropriate 
drug combinations to avoid complications, such as drug interactions and related 
adverse events.  Secondly, an older body reacts to pharmaceuticals quite differently 
than a youthful one due to the physiological changes that accompany aging:  
metabolism rates change, organ function declines, and sensitivity to some drugs can 
be altered.  Last, there is generally a wider variation of drug action in older patients; 
a medication that produces a desired effect for one seventy-year-old patient will not 
necessarily engender the same response in another.  Combined, these clinical 
variables point to a very real conclusion:  A “one drug fits all” approach cannot be 
applied to the older patient population. 
 
Though there is no lack of high-quality pharmaceutical agents in existence, optimal 
treatments can only be achieved if a wide range of drug options is made available.  
Unfortunately, restrictive drug policies, inadequate insurance plans, and increasing 
drug costs can limit the availability of pharmaceuticals for seniors.  Limited drug 
access could compromise the health of the elderly unnecessarily, leading to 
increased utilization of other medical services and increased overall costs.  Such 
outcomes are injurious to everyone involved:  patient, provider, plan and payer.   
 
Additional factors increase the risk of sub-optimal pharmaceutical care for older 
Americans.  Elderly patients often have a number of physicians (specialists and sub-
specialists included) providing for their care without any collaboration.  Physicians 
may or may not be cognizant of other healthcare providers treating their patient.  
Even when providers are aware of one another, discussion among these parties is 
not guaranteed.  In addition, patients may be self-treating with over-the-counter 
medications without informing their physicians.  Older patients, particularly the frail 
elderly, often receive care from separate treatment sites, a practice that provides 
little continuity.  What is greatly needed is the coordination of all drug treatments for 
an individual patient, across sites, providers and over time. 
 
No matter what we call the imminent demographic trend, there is no denying a 
population-wide age shift is coming.  To meet the challenges that this shift will 
present in the future, action is required now.  The keys to promoting quality care for 
seniors are to (1) provide patients with individualized drug therapy from a bank of 
therapeutic options; and (2) increase the coordination of care among all providers 
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and care sites.  Efforts toward the ultimate goal of a seamless continuum of 
individualized care represent the next stage in the evolution of geriatric pharmacy.   
 
As demographics shift, as “Boomers” approach their sixties, and as Congress 
addresses the possibility of Medicare drug benefits, the time to consider the issues in 
NOW.  If you are interested in exploring geriatric pharmaceutical therapy and its 
implications for drug benefit design and the future of coordinated care, you are 
encouraged to contact the Office of Health Policy and Clinical Outcomes regarding 
the recent publication, Why the Elderly Need Individualized Pharmaceutical Care.
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